Genmab

Genmab GMAB Stock

$51.83   0.504173%
Add to favorites
Market Cap
$31.96B
LOW - HIGH [24H]
$50.86 - $52.08
VOLUME [24H]
$2.44M
P/E Ratio
44.29
Earnings per share
$1.17
ISIN
US3723032062
Price   Prediction

Genmab Price Chart

Sorry, that's all we've gotfor now...

Genmab (GMAB) stock price today is 51.83 USD on Tech Market Large (+0.5% on the day). Updated .

Genmab GMAB Financial and Trading Overview

Genmab stock price 51.83 USD
Previous Close 51.37 USD
Open 52.66 USD
Bid 37.87 USD x 200
Ask 66.62 USD x 200
Day's Range 51.51 - 52.82 USD
52 Week Range 23.62 - 59.97 USD
Volume 2.41M USD
Avg. Volume 4.21M USD
Market Cap 31.8B USD
Beta (5Y Monthly) 0.518
PE Ratio (TTM) 44.076923
EPS (TTM) 1.17 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 65.01 USD

GMAB Valuation Measures

Enterprise Value 35.97B USD
Trailing P/E 44.076923
Forward P/E 32.63924
PEG Ratio (5 yr expected) 4.61
Price/Sales (ttm) 7.4017076
Price/Book (mrq) 5.1541653
Enterprise Value/Revenue 8.372
Enterprise Value/EBITDA 26.525

Trading Information

Genmab Stock Price History

Beta (5Y Monthly) 0.518
52-Week Change 68.86%
S&P500 52-Week Change 13.32%
52 Week High 59.97 USD
52 Week Low 23.62 USD
50-Day Moving Average 41.15 USD
200-Day Moving Average 31.54 USD

GMAB Share Statistics

Avg. Volume (3 month) 4.21M USD
Avg. Daily Volume (10-Days) 4.55M USD
Shares Outstanding 616.59M
Float 589.06M
Short Ratio 1.49
% Held by Insiders 0.10%
% Held by Institutions 20.89%
Shares Short 9.66M
Short % of Float 1.59%
Short % of Shares Outstanding 1.57%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 5:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 16.96%
Operating Margin (ttm) 30.63%
Gross Margin 92.66%
EBITDA Margin 31.56%

Management Effectiveness

Return on Assets (ttm) 8.24%
Return on Equity (ttm) 12.06%

Income Statement

Revenue (ttm) 4.3B USD
Revenue Per Share (ttm) 6.99 USD
Quarterly Revenue Growth (yoy) 16.10%
Gross Profit (ttm) 3.98B USD
EBITDA 1.36B USD
Net Income Avi to Common (ttm) 729M USD
Diluted EPS (ttm) 1.17
Quarterly Earnings Growth (yoy) -14.69%

Balance Sheet

Total Cash (mrq) 1.87B USD
Total Cash Per Share (mrq) 2.96 USD
Total Debt (mrq) 5.2B USD
Total Debt/Equity (mrq) 82.08 USD
Current Ratio (mrq) 2.454
Book Value Per Share (mrq) 10.0055

Cash Flow Statement

Operating Cash Flow (ttm) 875M USD
Levered Free Cash Flow (ttm) 854.88M USD

Profile of Genmab

Country United States
State N/A
City Copenhagen
Address Carl Jacobsens Vej 30
ZIP 2500
Phone 45 70 20 27 28
Website https://www.genmab.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 3244

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Q&A For Genmab Stock

What is a current GMAB stock price?

Genmab GMAB stock price today per share is 51.83 USD.

How to purchase Genmab stock?

You can buy GMAB shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Genmab?

The stock symbol or ticker of Genmab is GMAB.

Which industry does the Genmab company belong to?

The Genmab industry is Biotechnology.

How many shares does Genmab have in circulation?

The max supply of Genmab shares is 616.59M.

What is Genmab Price to Earnings Ratio (PE Ratio)?

Genmab PE Ratio is 44.29915000 now.

What was Genmab earnings per share over the trailing 12 months (TTM)?

Genmab EPS is 1.17 USD over the trailing 12 months.

Which sector does the Genmab company belong to?

The Genmab sector is Healthcare.

Genmab GMAB included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24224.61 USD —
-1.16
6.53B USD — 23989.09 USD — 24547.66 USD — — 6.53B USD —
us US Tech Global Select Market Com NQGS US 11935.5 USD —
-1.13
— — 11815.78 USD — 12090.12 USD — — — —
us US Tech Biotechnology NBI US 6992.94 USD —
-1.07
— — 6949.3 USD — 7058.02 USD — — — —
us US Tech Health Care IXHC US 1329.76 USD —
-0.97
— — 1323.81 USD — 1342.94 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
$2.2T
Total marketcap
$77.23B
Total volume
BTC 58.33%   •   ETH 9.98%
Dominance
Select currency